Navigation Links
Danish Hotspot in Personalized Medicine
Date:11/12/2007

COPENHAGEN, November 12 /PRNewswire/ -- The Danish biotech cluster known as Medicon Valley has, within a short period, grown into a global hotspot in the field of personalized medicine, and finds itself increasingly in favor among big pharma and big biotech. Experience Danish competencies at the 3rd Annual Personalized Medicine Meeting in San Francisco from 12th - 13th November.

With over 10 research institutions and 15-20 private companies engaged in personalized medicine, the Danish biotech cluster known as Medicon Valley has in record time become a strong player in currently one of the hottest research fields within the pharmaceutical industry.

Several of these Danish players operate on an individual basis, although many are also involved in collaborative research efforts, including the Danish Center for Translational Breast Cancer Research, the siRNA Delivery Center, the Danish microRNA consortium and special research departments at the University of Copenhagen and the Technical University of Denmark.

This is one reason why Denmark is participating in 3rd Annual Personalized Medicine Meeting in San Francisco, where Director of Knowledge and Communications at Danish Medicines Agency Kaare Geil is in the panel discussion on the second day to give a European/Danish perspective on the topic: Who Will Pay? The Economics of Personalized Medicine. Kaare Geil says: "Denmark has a national cancer plan, which is very clear on personalized medicine. The ministry of health as well as the ministry of science, has specific programs to support and enable the implementation of personalized medicines in our systems."

S0ren M. Echwald, M.Sc., Ph.D., who is Vice President and responsible for Business Development at Exiqon will be hosting a table discussion at the conference. "Exiqon is very committed to our diagnostic vision, and is active with several diagnostic projects," says S0ren M. Echwald. "With Exqion's key technologies, the growing role of microRNA in classification of cancers, and the strong clinical network in Scandinavia, we feel ideally positioned to contribute to the improvement of cancer treatment selection."

Business Development Manager Vibeke Dalhoff from Copenhagen Capacity, the official investment promotion agency of the Capital Region of Denmark explains: "Denmark is absolutely world-class within biomedicine and we are pioneers within personalized medicine, with strong competencies in the therapeutic and cancer fields, among others."

Gitte Pedersen, special advisor with the sister organization Invest in Denmark: "Denmark is in a unique position. We excel at developing medicine, we have core competencies within system biology, which is the toolbox for personalized medicine, and we have a health service that can see the advantages of implementing individualized medicine and engage in an open dialog between companies and the authorities".

Given this cocktail of companies, research environment and interest from the public sector, international pharmaceutical companies working on personalized medicine have a strong focus on Denmark and Medicon Valley.

"There is growing interest in the Danish competencies within individualized medicine", says Vibeke Dalhoff.

These companies work with personalized medicine in Denmark:

Within diagnostics: Dako, Exiqon, FluimediX and Medical Prognostic Institute.

Within drug discovery: Genmab, Novo Nordisk, Pharmexa, Santaris Pharma and TopoTarget.

For further information:

Vibeke Dalhoff

Tel.:+45-33-26-87-22

+45-61-26-464

email: vda@copcap.com

Gitte Pedersen

tel: +1-212-665-8626

email: gp@investindk.com


'/>"/>
SOURCE Copenhagen Capacity
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
2. HHS Issues First Department-Wide Report on Personalized Health Care
3. Agendia Joins the Personalized Medicine Coalition (PMC)
4. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
5. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
8. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
9. Companys Partner Completes Trial Production of a New Antiviral Medicine
10. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
11. Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
(Date:2/10/2016)... 10, 2016  Allergan plc (NYSE: AGN ) ... Brent Saunders , Allergan,s CEO and President, will be ... session at the RBC Capital Markets Healthcare Conference on ... The New York Palace Hotel in New ... live and can be accessed on Allergan,s Investor Relations ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... three states, announced today the promotion of two long-standing principal investigators (PI) to ... Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research ...
Breaking Biology Technology:
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
Breaking Biology News(10 mins):